Edward Ofori1, Xue Y Zhu1, Jagan R Etukala1, Kwakye Peprah1, Kamanski R Jordan1, Adia A Adkins1, Barbara A Bricker1, Hye J Kang2, Xi-Ping Huang2, Bryan L Roth3, Seth Y Ablordeppey1. 1. Division of Basic Pharmaceutical Sciences, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences, Tallahassee, FL 32307, USA. 2. Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365, USA; National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP), School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365, USA. 3. Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365, USA; National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP), School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365, USA; Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7360, USA.
Abstract
5-HT1A and 5-HT7 receptors have been at the center of discussions recently due in part to their major role in the etiology of major central nervous system diseases such as depression, sleep disorders, and schizophrenia. As part of our search to identify dual targeting ligands for these receptors, we have carried out a systematic modification of a selective 5HT7 receptor ligand culminating in the identification of several dual 5-HT1A and 5-HT7 receptor ligands. Compound 16, a butyrophenone derivative of tetrahydroisoquinoline (THIQ), was identified as the most potent agent with low nanomolar binding affinities to both receptors. Interestingly, compound 16 also displayed moderate affinity to other clinically relevant dopamine receptors. Thus, it is anticipated that compound 16 may serve as a lead for further exploitation in our quest to identify new ligands with the potential to treat diseases of CNS origin. Published by Elsevier Ltd.
5-HT1A and 5-HT7 receptors have been at the center of discussions recently due in part to their major role in the etiology of major n class="Disease">central nervous system diseases such as depression, sleep disorders, and schizophrenia. As part of our search to identify dual targeting ligands for these receptors, we have carried out a systematic modification of a selective 5HT7 receptor ligand culminating in the identification of several dual 5-HT1A and 5-HT7 receptor ligands. Compound 16, a butyrophenone derivative of tetrahydroisoquinoline (THIQ), was identified as the most potent agent with low nanomolar binding affinities to both receptors. Interestingly, compound 16 also displayed moderate affinity to other clinically relevant dopamine receptors. Thus, it is anticipated that compound 16 may serve as a lead for further exploitation in our quest to identify new ligands with the potential to treat diseases of CNS origin. Published by Elsevier Ltd.
Authors: Eva Agai-Csongor; György Domány; Katalin Nógrádi; János Galambos; István Vágó; György Miklós Keserű; István Greiner; István Laszlovszky; Anikó Gere; Eva Schmidt; Béla Kiss; Mónika Vastag; Károly Tihanyi; Katalin Sághy; Judit Laszy; István Gyertyán; Mária Zájer-Balázs; Larisza Gémesi; Margit Kapás; Zsolt Szombathelyi Journal: Bioorg Med Chem Lett Date: 2012-04-04 Impact factor: 2.823
Authors: Elena Silvano; Mark J Millan; Clotilde Mannoury la Cour; Yang Han; Lihua Duan; Suzy A Griffin; Robert R Luedtke; Gabriella Aloisi; Mario Rossi; Francesca Zazzeroni; Jonathan A Javitch; Roberto Maggio Journal: Mol Pharmacol Date: 2010-08-11 Impact factor: 4.436
Authors: Edward Ofori; Xue Y Zhu; Jagan R Etukala; Barbara A Bricker; Seth Y Ablordeppey Journal: Bioorg Med Chem Date: 2016-09-10 Impact factor: 3.641
Authors: Edem K Onyameh; Edward Ofori; Barbara A Bricker; Uma M Gonela; Suresh V K Eyunni; Hye J Kang; Chandrashekar Voshavar; Seth Y Ablordeppey Journal: Med Chem Res Date: 2021-09-23 Impact factor: 1.965
Authors: Edward Ofori; Edem K Onyameh; Uma M Gonela; Chandrashekhar Voshavar; Barbara Bricker; Tracy L Swanson; Amy J Eshleman; Jennifer L Schmachtenberg; Shelley H Bloom; Aaron J Janowsky; Seth Y Ablordeppey Journal: Eur J Med Chem Date: 2021-02-03 Impact factor: 6.514
Authors: Edem K Onyameh; Barbara A Bricker; Suresh V K Eyunni; Chandrashekhar Voshavar; Uma M Gonela; Edward Ofori; Andrea Jenkins; Seth Y Ablordeppey Journal: Bioorg Med Chem Date: 2020-12-14 Impact factor: 3.641